

CARVYKTI® (ciltacabtagene autoleucel) is a treatment used for adult patients who have cancer of the bone marrow called multiple myeloma. It is used when at least one other kind of treatment has not worked or has stopped working. CARVYKTI® is a medicine made from your own white blood cells, which have been changed (genetically modified) to recognize and attack your multiple myeloma cells.

For Care Partners

CARVYKTI® POST-INFUSION MONITORING GUIDE

Caring for Someone After a CARVYKTI® Infusion



IMPORTANT SAFETY INFORMATION

What is the most important information I should know about CARVYKTI®?

CARVYKTI® may cause side effects that are severe or life-threatening and can lead to death. Call your healthcare provider or get emergency help right away if you get any of the following:

- fever (100.4°F/38°C or higher)
- chills or shaking chills
- fast or irregular heartbeat
- difficulty breathing
- very low blood pressure
- dizziness/lightheadedness
- effects on your nervous system, some of which can occur days or weeks after you receive the infusion, and may initially be subtle such as:
 - feeling confused, less alert, or disoriented, having difficulty speaking or slurred speech, having difficulty reading, writing, and understanding words, memory loss
 - loss of coordination affecting movement and balance, slower movements, changes in handwriting
 - personality changes including a reduced ability to express emotions, being less talkative, disinterest in activities, and reduced facial expression
 - tingling, numbness, and pain of hands and feet, difficulty walking, leg and/or arm weakness, and difficulty breathing
 - facial numbness, difficulty moving muscles of face and eyes

Please read full [Important Safety Information](#).

Please read full [Prescribing Information, including Boxed Warning](#), and read the [Medication Guide](#). Discuss any questions you have with your healthcare team.



HOW YOU CAN SUPPORT SOMEONE POST-INFUSION

This guide is provided to help you as a care partner, and any other care partners who may be involved, be prepared to care for someone after they receive a CARVYKTI® (ciltacabtagene autoleucel) infusion. The recovery phase after the infusion is a crucial time, and your role as a care partner will be to help the person you are caring for as they go through the recovery experience after they leave the care of the Certified Treatment Center where they received CARVYKTI®.

It's normal to feel nervous or overwhelmed about what is expected of you. **You and the other care partners can make all the difference in the world for the person you are caring for—with your time, encouragement, and practical support.**

You don't have to manage this alone. Support is available to help you along the way, and you may want to identify friends or family who can help you as well.

Understanding what signs and symptoms of side effects to look for, and notifying the healthcare team as soon as you see one, is an important responsibility of care partners, in addition to:

Scheduling appointments

Providing transportation to appointments and keeping them company

Helping communicate with the healthcare providers (for example, providing medical and insurance information, asking questions)

Assisting with responsibilities at home

Providing emotional support and giving them someone to talk with

Managing their schedule and coordinating time for friends and family to visit

Coordinating care with other care partners to ensure someone is always available for the person you are caring for



PROVIDING ENCOURAGEMENT

Treating multiple myeloma can be challenging. You can help the person you are caring for with some of the daily struggles, such as eating right or talking through their emotions.

There's no way to anticipate everything you'll need to know as a care partner, but by becoming familiar with the disease and treatment, you can offer support to help the person you are caring for make informed decisions.

IMPORTANT SAFETY INFORMATION (more)

It is important that you tell your healthcare providers that you have received CARVYKTI® and to show them your CARVYKTI® Patient Wallet Card. Your healthcare providers may give you other medicines to treat your side effects.

Please read full [Important Safety Information](#).

Please read full [Prescribing Information, including Boxed Warning](#), and read the [Medication Guide](#). Discuss any questions you have with your healthcare team.



SHORT-TERM MONITORING AFTER THE ONE-TIME CARVYKTI® INFUSION

After the person you are caring for has received the one-time CARVYKTI® (ciltacabtagene autoleucel) infusion, they will continue to be monitored at the Certified Treatment Center where they received the infusion. The healthcare team will check to see that treatment is working and will work to manage any side effects that may occur. Serious side effects may require hospitalization until the side effects are under control and it is safe to leave the hospital.

WHAT TO EXPECT AFTER INFUSION



Daily monitoring for 10 days at the CARVYKTI® Certified Treatment Center

The person you are caring for will receive daily monitoring for any signs and symptoms of a reaction to treatment at the Certified Treatment Center for at least 10 days after the infusion. The healthcare provider will manage any side effects that may occur.



Stay close to the Certified Treatment Center for at least 4 weeks

You and the person you are caring for will stay within proximity of the Certified Treatment Center for at least 4 weeks. The healthcare provider will check to see that the treatment is working for the person you are caring for and will help manage any side effects that may occur.



CONTACT THE HEALTHCARE TEAM IMMEDIATELY IF YOU THINK YOU ARE SEEING SIGNS OR SYMPTOMS OF A SIDE EFFECT

As the care partner, you may be the first to notice subtle changes in the person you are caring for. If you notice any of the signs or symptoms listed on the next page, or if they think they are having any other signs of side effects, contact their healthcare provider or the Certified Treatment Center right away.

IMPORTANT SAFETY INFORMATION (more)

Before you receive CARVYKTI® tell your healthcare provider about all your medical conditions, including if you have:

- Current or past neurologic problems (such as seizures, stroke, new or worsening memory loss)
- Lung or breathing problems
- Heart problems

- Liver problems
- Kidney problems
- A recent or active infection
- Low blood counts

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.



Please read full [Important Safety Information](#).

Please read full [Prescribing Information, including Boxed Warning](#), and read the [Medication Guide](#). Discuss any questions you have with your healthcare team.

SHORT-TERM MONITORING AFTER THE ONE-TIME CARVYKTI® INFUSION (more)

AS A CARE PARTNER, BE AWARE OF CERTAIN SIGNS AND SYMPTOMS OF SIDE EFFECTS THAT COULD OCCUR

Signs and symptoms of cytokine release syndrome may include:				
• Fever	• Fatigue	• Nausea	• Headache	• Fast heartbeat
• Difficulty breathing	• Low blood pressure	• Dizziness or lightheadedness		
Signs and symptoms of life-threatening infections may include:				
• Fever	• Chills	• Any sign of infection		
Signs and symptoms associated with neurologic side effects, some of which may occur days or weeks following the infusion, may include:				
• Confusion	• Disorientation	• Loss of consciousness	• Seizures	• Leg and arm weakness
• Tremor	• Slower movements	• Changes in personality	• Depression	• Facial numbness
• Difficulty speaking, reading, or writing		• Tingling and numbness of hands and feet		
Signs and symptoms associated with cytopenias (low blood counts) may include:				
• Feeling tired	• Weakness	• Shortness of breath	• Any sign of infection	• Fever
• Bleeding and bruising	• Chills			

Regardless of how small it may seem, it's important to share with the healthcare team any side effects that develop. Some side effects can be serious, even life-threatening, and need to be identified and treated quickly. These are not all the side effects that can occur. Please refer to the [Medication Guide](#) for an extensive list of signs and symptoms to watch for.



MONITORING FOR SYMPTOMS OF NEUROLOGIC SIDE EFFECTS

Always alert the healthcare team if you recognize any changes in the person you are caring for, so the team can assess the patient as quickly as possible. One of these assessments may include the ICE test, which can help detect a neurologic side effect called ICANS. The ICE test includes asking the person you are caring for to answer simple questions and perform certain exercises, such as:

- 1. Orientation:** Recalling what month and year it is.
- 2. Naming:** Pointing to certain objects in the room.
- 3. Following commands:** "Show me 2 fingers."
- 4. Writing:** Ability to write a standard sentence.
- 5. Attention:** "Can you count backwards from 100 by tens?"

ICANS=immune effector cell-associated neurotoxicity syndrome; ICE=immune effector cell-associated encephalopathy.

IMPORTANT SAFETY INFORMATION (more)

How will I receive CARVYKTI®?

- CARVYKTI® is made from your own white blood cells, so your blood will be collected by a process called 'leukapheresis' (loo-kah-fur-ee-sis). The procedure can take 3 to 6 hours and may need to be repeated.

- Your white blood cells are sent to a manufacturing center to make CARVYKTI®. It takes about 4-5 weeks from the time your cells are received at the manufacturing site and are available to be shipped back to your healthcare provider, but the time may vary.



Please read full [Important Safety Information](#).

Please read full [Prescribing Information, including Boxed Warning](#), and read the [Medication Guide](#). Discuss any questions you have with your healthcare team.

LONG-TERM CARE AND MONITORING

After the initial 4-week monitoring period at or near the Certified Treatment Center, your healthcare team will determine when you and the person you are caring for may return home. When this happens, the primary oncology team will continue to provide care and partner with you to create a plan for long-term monitoring and regular follow-up visits.

KEEP THESE ADDITIONAL GUIDELINES IN MIND FOR LONG-TERM CARE

- Keep monitoring**
Continue monitoring for signs and symptoms of side effects. Side effects may develop even after you and the person you are caring for have returned home.
- Secure a driver**
Ensure the person you are caring for has a driver to take them to all appointments and other places requiring travel. The person you are caring for must refrain from driving or hazardous activities for at least 8 weeks following infusion.
- Schedule ahead**
Make sure all of the important appointments with the primary oncologist are scheduled and ensure that you or another care partner is able to attend those visits.



WATCHING OUT FOR SIDE EFFECTS

You are an extra set of eyes and ears for the healthcare providers. As someone who knows the person you are caring for better than the healthcare providers, you may notice changes in behavior, personality, or handwriting sooner than they do. Alert the healthcare team quickly if you notice any signs or symptoms or you think the person you are caring for is having a side effect. Be observant and be prepared by keeping the names and phone numbers of the healthcare team nearby in the event you have any questions or a side effect occurs.



Visit [CARVYKTI.com](https://www.carvykti.com) to find more resources and support for you, including a guide to help monitor for side effects.



Download the **Care Partner Checklist** for a quick reference to providing support during the CARVYKTI® treatment journey

IMPORTANT SAFETY INFORMATION (more)

- While CARVYKTI® is being made, you may get other medicines to treat the multiple myeloma. This is so that your multiple myeloma does not get worse.

Before you get CARVYKTI®, your healthcare provider will give you chemotherapy for 3 days to prepare your body.

30 to 60 minutes before you are given CARVYKTI®, you may be given other medicines. These may include:

- medicines for an allergic reaction (antihistamines)
- medicines for fever (such as acetaminophen)

When your CARVYKTI® is ready, your healthcare provider will give CARVYKTI® to you through a catheter (tube) placed into your vein (intravenous infusion). Your dose of CARVYKTI® will be given in one infusion bag. The infusion usually takes approximately 30-60 minutes.

Please read full [Important Safety Information](#).

Please read full [Prescribing Information, including Boxed Warning](#), and read the [Medication Guide](#). Discuss any questions you have with your healthcare team.



TAKING CARE OF YOUR OWN NEEDS

Caring for someone with multiple myeloma is time-consuming. It's easy to get so immersed in caring for them that you neglect your own physical, mental, and emotional health. This can lead to burnout. That's why it's so important to pay attention to your well-being. Your needs as a care partner are distinct from the needs of the person you are caring for. These tips can help you stay focused on giving the long-term support that is needed.

TAKE TIME FOR YOURSELF

Carve out time specifically for resting and doing things you enjoy. Some ideas include:

Napping

Eating a fresh, healthy meal

Exercising or doing yoga

Keeping up with a hobby

Taking a drive

Seeing a movie

Working in the yard

Going shopping

Catching up on phone calls, letters, or email

Journaling or meditating



CONSIDER AVAILABLE SUPPORT

It's good to have help with caregiving responsibilities, but having consistent support for your needs is also important. Consider finding a support group or talking to a counselor. You can ask your healthcare facility for support and resources that may be available through the hospital, or refer to the list of support and advocacy groups for care partners at [CARVYKTI.com](https://www.carvykti.com).



ALMOST HALF OF CARE PARTNERS FOR SOMEONE WITH MULTIPLE MYELOMA SUFFER FROM ANXIETY

Your circumstances will be unique to you, but there are many reasons why you may experience symptoms of anxiety. These can include managing medical needs, navigating the healthcare system, fears about disease relapse, financial or work-related concerns, navigating shifts in your relationships, or even changes in intimacy. You are not alone in facing these challenges, and it is not a sign of failure if you need help or need to take care of yourself.

IMPORTANT SAFETY INFORMATION (more)

After getting CARVYKTI®, you will be monitored at the certified healthcare facility where you received your treatment for at least 10 days after the infusion.

You should plan to stay close to the location where you received your treatment for at least 4 weeks. Your healthcare provider will check to see that your treatment is working and



Please read full [Important Safety Information](#).

Please read full [Prescribing Information, including Boxed Warning](#), and read the [Medication Guide](#). Discuss any questions you have with your healthcare team.

DEFINITIONS OF SIDE EFFECTS

Always feel free to ask your healthcare team to define a term if it is unfamiliar to you or the person you are caring for. The terms below are some common side effects. Alert the healthcare team quickly if any side effects occur.

To learn more about side effects, download the [Monitoring for Potential Side Effects Guide](#) brochure.

Cranial nerve palsy—paralysis of the nerves that send information between the brain and the sense organs (the eyes, ears, nose, and tongue). They also send information to the muscles in the face, head, neck, and other organs in the body, including the larynx (voice box), heart, lungs, stomach, and intestines.

Cytokine release syndrome (CRS)—a condition that can occur after some types of immunotherapy treatment, such as treatment with monoclonal antibodies and CAR-T cell infusions. CRS is caused by the rapid release of cytokines into the blood from immune cells affected by the immunotherapy. Cytokines are immune substances that have many different purposes in the body. Most patients have a mild reaction, but sometimes the reaction may be severe or life-threatening.

Cytopenia—a condition in which there is a lower-than-normal number of blood cells.

Guillain-Barré syndrome (GBS)—a rare condition in which the body's immune system attacks the nerves located outside the brain and spinal cord. Symptoms include muscle weakness, muscle pain, numbness, and tingling. Other symptoms may include problems with vision, speech, swallowing, digestion, and bladder control.

Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS)—a rare disorder in which various types of white blood cells build up in organs, including the skin, spleen, and liver, and destroy other blood cells, possibly leading to organ failure.

Hypogammaglobulinemia—a condition in which the level of antibodies in the blood is low and the risk of infection is high.

Immune effector cell-associated neurotoxicity syndrome (ICANS)—a clinical and neuropsychiatric syndrome that can occur in the days to weeks following administration of certain types of immunotherapy, especially immune effector cell (IEC) and T cell engaging therapies.

Immune-mediated myelitis—immune-mediated inflammatory diseases (IMIDs) is an umbrella term that encompasses a number of common, chronic and complex disorders, characterized by a dysregulation or abnormality of the normal immune response which leads to inflammation in target organs and, usually, systemic effects as well. Myelitis refers to inflammation of the spinal cord. It can damage the insulating material, called myelin, that covers nerve cell fibers.

Neurologic toxicity—occurs when the exposure to toxic substances alters the normal activity of the nervous system. This can eventually disrupt neurons (key cells that transmit and process signals in the brain and other parts of the nervous system). Neurologic toxicity can result from exposure to substances used in chemotherapy, radiation treatment, drug therapies, and organ transplants, or exposure to other substances. Individuals with certain disorders may be especially vulnerable to substances that can cause neurologic toxicities.

Parkinsonism—refers to symptoms of Parkinson's disease, including slow movements and tremors that are caused by another condition or certain drugs and toxins.

Peripheral neuropathy—a nerve problem that can cause pain, numbness, tingling, swelling, or muscle weakness in different parts of the body. It is frequently caused by cancer or cancer treatments, such as chemotherapy.



BEING AN ADVOCATE

It's important to be an advocate for the person you are caring for. If they or you have questions about any part of treatment, ask a member of the Certified Treatment Center staff. They expect you to have lots of questions, and they understand that providing answers to your questions is an important part of a successful treatment.

IMPORTANT SAFETY INFORMATION (more)

help you with any side effects that may occur. You may be hospitalized if you develop serious side effects until your side effects are under control and it is safe for you to leave the hospital.

Your healthcare provider will want to do blood tests to follow your progress. It is important that you have your blood tested. If you miss an appointment, call your healthcare provider as soon as possible to reschedule.



Please read full [Important Safety Information](#).

Please read full [Prescribing Information, including Boxed Warning](#), and read the [Medication Guide](#). Discuss any questions you have with your healthcare team.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about CARVYKTI®?

CARVYKTI® may cause side effects that are severe or life-threatening and can lead to death. Call your healthcare provider or get emergency help right away if you get any of the following:

- fever (100.4°F/38°C or higher)
- chills or shaking chills
- fast or irregular heartbeat
- difficulty breathing
- very low blood pressure
- dizziness/lightheadedness
- effects on your nervous system, some of which can occur days or weeks after you receive the infusion, and may initially be subtle such as:
 - feeling confused, less alert, or disoriented, having difficulty speaking or slurred speech, having difficulty reading, writing, and understanding words, memory loss
 - loss of coordination affecting movement and balance, slower movements, changes in handwriting
 - personality changes including a reduced ability to express emotions, being less talkative, disinterest in activities, and reduced facial expression
 - tingling, numbness, and pain of hands and feet, difficulty walking, leg and/or arm weakness, and difficulty breathing
 - facial numbness, difficulty moving muscles of face and eyes

It is important that you tell your healthcare providers that you have received CARVYKTI® and to show them your CARVYKTI® Patient Wallet Card. Your healthcare providers may give you other medicines to treat your side effects.

Before you receive CARVYKTI® tell your healthcare provider about all your medical conditions, including if you have:

- Current or past neurologic problems (such as seizures, stroke, new or worsening memory loss)
- Lung or breathing problems
- Heart problems
- Liver problems
- Kidney problems
- A recent or active infection
- Low blood counts

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive CARVYKTI®?

- CARVYKTI® is made from your own white blood cells, so your blood will be collected by a process called 'leukapheresis' (loo-kah-fur-ee-sis). The procedure can take 3 to 6 hours and may need to be repeated.



Please read full [Important Safety Information](#).

Please read full [Prescribing Information, including Boxed Warning](#), and read the [Medication Guide](#). Discuss any questions you have with your healthcare team.

IMPORTANT SAFETY INFORMATION (more)

- Your white blood cells are sent to a manufacturing center to make CARVYKTI®. It takes about 4-5 weeks from the time your cells are received at the manufacturing site and are available to be shipped back to your healthcare provider, but the time may vary.
- While CARVYKTI® is being made, you may get other medicines to treat the multiple myeloma. This is so that your multiple myeloma does not get worse.

Before you get CARVYKTI®, your healthcare provider will give you chemotherapy for 3 days to prepare your body.

30 to 60 minutes before you are given CARVYKTI®, you may be given other medicines. These may include:

- medicines for an allergic reaction (antihistamines)
- medicines for fever (such as acetaminophen)

When your CARVYKTI® is ready, your healthcare provider will give CARVYKTI® to you through a catheter (tube) placed into your vein (intravenous infusion). Your dose of CARVYKTI® will be given in one infusion bag. The infusion usually takes approximately 30-60 minutes.

After getting CARVYKTI®, you will be monitored at the certified healthcare facility where you received your treatment for at least 10 days after the infusion.

You should plan to stay close to the location where you received your treatment for at least 4 weeks. Your healthcare provider will check to see that your treatment is working and help you with any side effects that may occur. You may be hospitalized if you develop serious side effects until your side effects are under control and it is safe for you to leave the hospital.

Your healthcare provider will want to do blood tests to follow your progress. It is important that you have your blood tested. If you miss an appointment, call your healthcare provider as soon as possible to reschedule.

What should I avoid after receiving CARVYKTI®?

- Do not drive, or operate heavy machinery, or do other activities that could be dangerous if you are not mentally alert, for at least 8 weeks after you get CARVYKTI®. This is because the treatment can cause memory and coordination problems, sleepiness, confusion, dizziness, seizures, or other neurologic side effects as discussed by your healthcare provider.
- You must not be given certain vaccines called live vaccines for some time before and after CARVYKTI® treatment. Talk to your healthcare provider if you need to have any vaccinations.
- Do not donate blood, organs, tissues, or cells for transplantation.

What are the possible or reasonably likely side effects of CARVYKTI®?

The most common side effects of CARVYKTI® include:

- fever (100.4°F/38°C or higher), chills
- dizziness or light-headedness
- headache, muscle or joint pain, feeling very tired
- altered mental state, confusion
- infections
- low levels of antibodies (immunoglobulins) in the blood
- cough, being short of breath



Please read full [Important Safety Information](#).

Please read full [Prescribing Information, including Boxed Warning](#), and read the [Medication Guide](#). Discuss any questions you have with your healthcare team.

IMPORTANT SAFETY INFORMATION (more)

- diarrhea, nausea, decreased appetite, constipation
- fast or irregular heartbeat
- problems with blood clotting

In a study comparing CARVYKTI® to standard therapy, there was a higher rate of death in the first 10 months in the CARVYKTI® arm (14%) compared to the standard therapy arm (12%). The increased rate of deaths occurred before receiving CARVYKTI® and after treatment with CARVYKTI®. The reasons for death were progression of multiple myeloma and side effects of the treatment.

CARVYKTI® can cause a very common side effect called cytokine release syndrome or CRS, which can be severe or fatal. Symptoms of CRS include fever, difficulty breathing, dizziness or lightheadedness, nausea, headache, fast heartbeat, low blood pressure, or fatigue. Tell your healthcare provider right away if you develop fever or any of these other symptoms after receiving CARVYKTI®.

CARVYKTI® can increase the risk of life-threatening infections including COVID-19 that may lead to death. Tell your healthcare provider right away if you develop fever, chills, or any signs or symptoms of an infection.

CARVYKTI® can cause various neurologic side effects, some of which may be severe or fatal. Symptoms include but are not limited to confusion, disorientation, loss of consciousness, seizures, difficulty speaking, reading or writing, tremor, slower movements, changes in personality, depression, tingling and numbness of hands and feet, leg and arm weakness, and facial numbness.

CARVYKTI® can lower one or more types of your blood cells (red blood cells, white blood cells, or platelets [cells that help blood to clot]), which may make you feel weak or tired, or increase your risk of severe infection or bleeding that may lead to death. After treatment, your healthcare provider will test your blood to check for this. Tell your healthcare provider right away if you get a fever, chills, or any signs or symptoms of an infection, are feeling tired, or have bruising or bleeding.

CARVYKTI® may increase your risk of getting cancers including certain types of blood cancers. Your healthcare provider should monitor you for this.

Having CARVYKTI® in your blood may cause some commercial Human Immunodeficiency Virus (HIV) tests to incorrectly give you an HIV-positive result even though you may be HIV-negative.

These are not all the possible side effects of CARVYKTI®. Call your healthcare provider if you have any side effects.

You may report side effects to FDA at 1-800-FDA-1088.

Please read full [Prescribing Information](#), including Boxed Warning, for CARVYKTI®.

cp-258861v6



© Janssen Biotech, Inc. 2024
© Legend Biotech 2024
All rights reserved. 05/24 cp-346627v3



Please read full [Important Safety Information](#).

Please read full [Prescribing Information, including Boxed Warning](#), and read the [Medication Guide](#). Discuss any questions you have with your healthcare team.